Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance (Use Result Surveillance) With Refixia®. A Multicentre, Non-interventional Post Marketing Surveillance of Safety and Effectiveness of Refixia® in Routine Clinical Care With Haemophilia B Patients in Japan.

NCT03875547 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03875547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03875547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance (Use Result Surveillance) With Refixia®. A Multicentre, Non-interventional Post Marketing Surveillance of Safety and Effectiveness of Refixia® in Routine Clinical Care With Haemophilia B Patients in Japan.
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
August 23, 2019
Completion date
September 30, 2025
Enrollment
28 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilia b